Kiniksa Pharmaceuticals Terminates Material Agreement

Ticker: KNSA · Form: 8-K · Filed: 2025-02-25T00:00:00.000Z

Sentiment: neutral

Topics: agreement-termination, financial-condition, operations

TL;DR

Kiniksa terminated a big deal, expect financial updates soon.

AI Summary

On February 21, 2025, Kiniksa Pharmaceuticals International, plc filed an 8-K reporting the termination of a material definitive agreement. The filing also covers results of operations, financial condition, and costs associated with exit or disposal activities. Specific details regarding the agreement termination and financial impact are expected to be further elaborated in the filing.

Why It Matters

The termination of a material definitive agreement can significantly impact a company's operations, financial performance, and future strategic direction.

Risk Assessment

Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding future revenue streams and operational stability.

Key Players & Entities

FAQ

What was the material definitive agreement that was terminated?

The filing indicates the termination of a material definitive agreement, but the specific details of the agreement are not provided in this summary.

What are the financial implications of this termination?

The filing mentions 'Results of Operations and Financial Condition' and 'Cost Associated with Exit or Disposal Activities,' suggesting financial impacts are being reported, but specific figures are not detailed here.

When did the termination become effective?

The earliest event reported is February 21, 2025, which is the date of the report.

Is this termination expected to affect Kiniksa's ongoing operations?

The termination of a material definitive agreement typically has implications for ongoing operations, which would be detailed further within the full filing.

What is the nature of the 'Cost Associated with Exit or Disposal Activities'?

This item suggests that there are costs incurred due to the termination or disposal of assets or operations related to the terminated agreement, as detailed in the full filing.

From the Filing

0001104659-25-016725.txt : 20250225 0001104659-25-016725.hdr.sgml : 20250225 20250225073119 ACCESSION NUMBER: 0001104659-25-016725 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250221 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25659409 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 8-K 1 tm257489d1_8k.htm FORM 8-K false 0001730430 0001730430 2025-02-21 2025-02-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 21, 2025   Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)   England and Wales   001-730430   98-1795578 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)   23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom (Address of principal executive offices, including zip code)   ( 781 ) 431-9100 (Registrant’s telephone number, including area code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Class A Ordinary Shares, $0.000273235 nominal value   KNSA   The Nasdaq Stock Market LLC         (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨         Item 1.02. Termination of a Material Definitive Agreement.   On February 21, 2025, a wholly-owned subsidiary of Kiniksa Pharmaceuticals International, plc (toget

View on Read The Filing